Related Experiment Video
Updated: May 18, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
In vitro functional characterization of missense mutations in the LDLR gene
1Grupo de Investigação Cardiovascular, Unidade I&D, Departamento de Promoção da Saúde e Doenças Crónicas, Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa 1649-040, Portugal.
Atherosclerosis
|October 2, 2012
Summary
Determining the pathogenicity of LDL receptor gene variants is crucial for diagnosing familial hypercholesterolaemia (FH). Functional assays revealed that some LDLR variants severely impair receptor function, impacting cardiovascular risk assessment.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Disease Research
Background:
- Mutations in the LDL receptor (LDLR) gene are a primary cause of familial hypercholesterolaemia (FH).
- Identifying LDLR gene variations does not automatically confirm pathogenicity for FH.
- The pathogenicity of five missense alterations in the LDLR gene was investigated.
Purpose of the Study:
- To assess the functional impact of specific LDLR gene missense variants.
- To differentiate pathogenic mutations from silent variants in FH patients.
- To understand the clinical implications for cardiovascular risk.
Main Methods:
- In vitro analysis using stably transfected CHO-ldlA7 cells.
- Immunoblotting, LDL uptake and degradation assays, and immunofluorescence microscopy.
- In silico analysis of sequence variants.
Main Results:
- Three LDLR variants (p.V429L, p.W490R, p.S648P) severely impaired receptor function.
- One variant (p.P685S) showed a milder effect on LDLR function.
- One variant (p.V859M) had LDL clearance rates comparable to normal LDLR; in silico analysis was unreliable for 4/5 variants.
Conclusions:
- Functional assessment is vital to distinguish pathogenic LDLR mutations from rare silent variants in FH.
- Accurate pathogenicity determination has significant clinical implications for cardiovascular risk stratification in FH patients.
